An observational study in Ulcerative Colitis (UC) and Colorectal Cancer (CRC), sponsored by Radboud University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Radboud University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Colitis, Ulcerative with a site in Netherlands — 25 open to participants now, 44 under way, 21 of them phase 3. Colitis, Ulcerative · Netherlands.
Among the 164 studies in Colitis, Ulcerative with a site in Netherlands, this one is the 24th largest by planned enrollment of the 25 observational ones that give a count, is one of 9 that started in 2025, is one of 25 observational ones, reaches primary completion later than 13 of the 43 other live ones, and was the 154th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →25 of the 164 studies in Colitis, Ulcerative with a site in Netherlands are open now. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18–75
Janssen Research & Development, LLC · Sites in Netherlands, United States, Argentina and 30 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Canada and 9 more countries
Ages 18–75
Sanofi · Sites in Netherlands, United States, Argentina and 28 more countries
Ages 16–80
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 54 · Phase 3 62 · Phase 4 8
First in 2001; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 165 across the 139 interventional studies, 355 across the 25 observational. Of the 106 that completed or were terminated, 59 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
111 of 164 have an industry lead sponsor. The 10 most frequent:
Radboud University Medical Center is the lead sponsor of 986 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Radboud University Medical Center has 4 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
8 of the studies in Colitis, Ulcerative with a site in Netherlands that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07582458Phase 3Radboud University Medical CenterModafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) | 2027-02-01 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT06723418University of GlasgowDevelopment and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS) | 2026-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 164 studies in Colitis, Ulcerative with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational pilot study with invasive measurements is to explore whether an ingestible sensor pill can be of use in diagnosis or monitoring of disease in patients with ulcerative colitis or colorectal cancer. The main questions it aims to answer are:
Participants will:
Rationale: The gold standard diagnostic tool for inflammatory bowel disease (IBD) and colorectal carcinoma (CRC) is endoscopy, which can be burdensome for patients. The future of IBD care demands novel, minimally invasive biomarkers for personalized care and CRC screening programs could greatly benefit from new minimally invasive diagnostic tools. Oxidative stress plays a significant role in the progression of gut inflammation and colorectal cancer. Using an ingestible sensor, we aim to measure oxidation-reduction potential (ORP) directly in the gut. We hypothesize that it is feasible to measure intestinal ORP with an ingestible sensor and expect that ORP levels are elevated in patients with active ulcerative colitis (UC) and CRC before treatment, compared to after treatment.
Objective: Measurement of intestinal oxidation-reduction potential using a smart sensing ingestible and its relation to active UC and CRC.
Study design: Observational, exploratory study with invasive measurements.
Study population: 5 patients ≥ 18 years of age with UC and 5 patients ≥ 18 years of age with CRC
Main study parameters/endpoints: The main study parameter is colonic ORP profiles measured with the ingestible sensor ingestible compared before and after treatment for UC and CRC.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Risk associated with participation are deemed low. Medical or surgical treatment is not altered in any way. Patients with UC will receive an additional IUS. The GISMO GEN1 ingestible device (size 21.8 mm x 7.64 mm) is an investigational tool deemed safe for human use in clinical settings, with risks detailed in the IMDD. Device exit will be tracked via the temperature sensor of the ingestible sensor. If exit is not confirmed after 14 days, an X-ray will confirm whether the device is still in the gastrointestinal tract. If visible on the X-ray, a medical specialist will determine further action, which may include laxatives or surgery, with costs covered by the research team. If X-ray examination is necessary, the participant may experience a maximum radiation exposure of 0.10 mSv. Participant burden is low; time investment including study visits, device checks and questionnaire is estimated around 4 hours in total. Main burden is expected to be the continuous wearing of the base device as long as the ingestible sensor remains in the body.
This study will be performed in outpatients ≥18 years old. Five patients will be included with moderately to severely active UC, starting new treatment; five patients with colorectal adenocarcinoma, planned for surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(For all participants:)
(For the UC group:)
(For the CRC group:)
Exclusion Criteria:
(For all participants:)
(For the CRC group:)
(For the UC population:)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Ingestion of sensor capsule (twice) · Behavioral: Device evaluation questionnaire · Device: Wearing device · Behavioral: Monitoring sensor capsule exit · Device: Placement of devices at home · Diagnostic Test: Follow-up intestinal ultrasound
Device: Ingestion of sensor capsule (twice) · Behavioral: Device evaluation questionnaire · Device: Wearing device · Behavioral: Monitoring sensor capsule exit · Device: Placement of devices at home
Ingestion of the GISMO GEN1 System, an ingestible sensor capsule which measures pH, temperature and oxidation reduction potential (ORP) in the intestines.
Also known as: GISMO GEN1 System
A 16-item online questionnaire to assess participant's experiences with the ingestible sensor capsule after the study measurements.
Participants will wear a small device on a soft belt around their waist during study measurements with the sensor capsules.
Participants are instructed to press a button on the wearable device when they use the toilet for defaecation and wait with flushing to toilet until the wearable device indicates (using colored LEDs) that the toilet can be flushed and 1) that the sensor capsule is still in the body and study measurements continue or 2) that the sensor capsule has likely been excreted via the feces and the participant has to contact the research team to confirm exit.
Participants do not have to wear the device around the waist during sleeping. For optimal monitoring of sensor capsule exit during the nights, a second device will be placed on the participant's bedside table/close to the bed and a third device will be placed close to the toilet that the participant usually uses during the night.
At 3 months after treatment initiation, participants with ulcerative colitis will undergo a follow-up intestinal ultrasound (IUS) (non-endoscopic) outside of routine care to assess treatment response.
Intestinal ORP measurements
ORP profile in the colon using the GISMO GEN1 System in patients with UC or CRC.
Time frame: Baseline and at 3 months after start of treatment.
Disease activity (SCCAI)
UC disease activity as determined by the Simple Clinical Colitis Activity Index
Time frame: Baseline and 3 months after start of treatment.
Disease activity (FC)
UC disease activity as determined by the faecal calprotectin (in microgram/gram)
Time frame: Baseline and at 3 months after treatment start.
Tumor stage
TNM tumor stage as recorded in pathology report.
Time frame: Directly after surgical resection
Tumor size
Tumor size as recorded in surgery report.
Time frame: Directly after surgical resection
Tumor resection margin status
Residual tumor at the primary site after surgical resection as classified in pathology report.
Time frame: Directly after surgical resection
Tumor differentiation grade
Tumor differentiation grade as recorded in pathology report.
Time frame: Directly after surgical resection
Intestinal pH
Intestinal pH measured with the ingestible sensor capsule.
Time frame: From enrollment to 3 months after start of treatment.
Area of inflammation
Area of inflammation in patients with UC, as recorded in the intestinal ultrasound report.
Time frame: Directly after intestinal ultrasound.
Tumour location
Tumor location in patients with CRC as recorded in the surgery report.
Time frame: Directly post-surgery.
Ingestible transit time.
Time from ingestion to defaecation in hours.
Time frame: Baseline and at 3 months after start of treatment.
Data coverage
Data coverage of recordings with the ingestible sensor capsule in minutes of data recorded as percentage of transit time in minutes (%)
Time frame: Baseline and at 3 months after start of treatment
Participant experience
Participant experience determined with a satisfaction questionnaire.
Time frame: Up to 1 month after exit of the post-treatment ingestible sensor capsule measurement period.
Plan to share: No — The data that supports the findings of this study can be made available upon request to the corresponding author within the regulations of the applicable regulations and ethical considerations.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Mar 2026, 8 months after the start.
Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 8 months is below that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Radboud University Medical Center →